MARKET WIREInvesting.com • 15m ago
Q32 Bio CEO Jodie Morrison sells $26,798 in stockInvesting.com report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
Why QTTB Stock advanced +0.45% Today — RQD Quant Desk Flash
$8.91 +0.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.90
Q32 Bio Inc. (QTTB) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $264.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on QTTB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is QTTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Q32 Bio Inc. (NASDAQ: QTTB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $8.91 (+0.45% 1D, market cap $264.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, QTTB ranks #259 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does QTTB compare to AMRN and BCYC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QTTB carries a Roarable D+ (53/100 RQD), trailing P/E of 8.9x, gross margin of —, and ROIC of 85.0%. By comparison, AMRN (Amarin Corporation plc) holds a D- grade (35/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M) and BCYC (Bicycle Therapeutics plc) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $267.4M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for QTTB?
▼
Per QTTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661998), Q32 Bio Inc. generated $53.7M in revenue, $29.8M in net income, and -$33.5M in free cash flow against $61.8M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.90 (-0.11%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QTTB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY QTTB SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (30% of score)
Altman Z-Score 5.99 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$8.74-10.9% Next Q
45
Q2 (-2Q)Grade D$7.79+8.5% Next Q
48
Q3 (-1Q)Grade C-$8.45+5.4% Next Q
50
CurrentGrade D+$8.91-0.9% Hist 90D α
53
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a QTTB Turnaround Squeeze
While QTTB currently carries a cautious 53/100 (D+) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Clean SEC annual filing review with no major hidden accounting time-bombs.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.31) and Max Pain ($9.36) forces dealer call-delta covering toward $24.75.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $QTTB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QTTB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why QTTB Stock advanced +0.45% Today — RQD Quant Desk Flash
Q32 Bio Inc. (QTTB) advanced +0.45% to $8.91, trading at 32% of its 52-week range ($1.9 – $23.57). Stretched risk/reward at 9x P/E (85% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 32% of its 52-week range ($1.9 – $23.57) with RSI-14 at 47.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.91 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live QTTB Headlines & Catalysts
MARKET WIREStock Titan • 3h ago
Q32 Bio (QTTB) scientific chief sells 917 shares automatically to cover tax withholding.Stock Titan report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 6h ago
Does ITT (ITT) Have the Potential to Rally 28.5% as Wall Street Analysts Expect?Yahoo Finance report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 9h ago
BIOA Stock Price and Chart — NASDAQ:BIOATradingView report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 12h ago
Bank of America reports a passive Q32 Bio (QTTB) stake for itself and three subsidiaries.Stock Titan report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 15h ago
Q32 bio CSO Shelia Violette sells $7,629 of company stock By Investing.comInvesting.com UK report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 18h ago
Q32 (QTTB) Slides -1.70% as Selling Pressure Mounts 2026-10-24 - Wave Equalityhttps://www.siam.in/ report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 21d ago
Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40Leerink Partners analyst Will Soghikian initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $40.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QTTB)
- ✓Walkthrough of QTTB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
QTTB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +76.79%⚡ TESTING RESISTANCE
2026-11-02O $9.06H $9.06L $8.87C $8.91VOL 317.9K
RES: $9.02SUP: $6.72SMA50: $10.31SMA200: $9.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
QTTB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-3.4%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on QTTB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for QTTB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QTTB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTTB)
Health Care Rank #259 of 1016
⚔️ AMRN vs QTTB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (QTTB vs. AMRN, BCYC, ABEO, IMRX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Q32 Bio Inc. (QTTB) ranks #259 by composite RQD confidence (53/100, grade D+) and #537 by equity capitalization ($264.1M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently leads its immediate peer cohort in composite quantitative strength at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QTTB
ACTIVE
Q32 Bio Inc. | D+ | 53/100 | 8.9x | — | 85.0% | +0.45% | $264.1M | Benchmark Subject |
| AMRN Amarin Corporation plc | D- | 35/100 | — | 56.6% | -12.2% | -4.91% | $262.8M | /amrn-vs-qttb → |
| BCYC Bicycle Therapeutics plc | E | 21/100 | — | — | -35.0% | -4.19% | $267.4M | /bcyc-vs-qttb → |
| ABEO Abeona Therapeutics Inc. | E | 23/100 | — | 73.7% | -35.0% | -4.61% | $260.8M | /abeo-vs-qttb → |
| IMRX Immuneering Corporation (Class A) | E | 32/100 | — | — | -35.0% | -6.84% | $260.1M | /imrx-vs-qttb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001661998In its most recent audited fiscal period (FY2025, filed 2025-12-31), Q32 Bio Inc. (QTTB) reported GAAP revenue of $53.7M (N/A vs. FY2024 revenue of $0 , and +4548.5% cumulative change since FY2023) , GAAP net income of $29.8M, operating cash flow of -$33.5M, and free cash flow of -$33.5M (+50.5% YoY). On the balance sheet, QTTB closed FY2025 with $61.8M in total assets against $0 in total debt (Altman Z-Score: 5.99, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $53.7M | $29.8M | -$33.5M | -$33.5M | $61.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$47.7M | -$67.7M | -$67.8M | $92.3M | — |
| FY2023 (FY) | 2023-12-31 | $1.2M | -$53.7M | -$18.7M | -$18.7M | — | — |
3. QTTB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs QTTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Q32 Bio Inc. (NASDAQ: QTTB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $8.91 (+0.45% 1D, market cap $264.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, QTTB ranks #259 in composite RQD confidence.
How does QTTB compare to AMRN and BCYC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QTTB carries a Roarable D+ (53/100 RQD), trailing P/E of 8.9x, gross margin of —, and ROIC of 85.0%. By comparison, AMRN (Amarin Corporation plc) holds a D- grade (35/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M) and BCYC (Bicycle Therapeutics plc) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $267.4M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for QTTB?
Per QTTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661998), Q32 Bio Inc. generated $53.7M in revenue, $29.8M in net income, and -$33.5M in free cash flow against $61.8M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is QTTB trading relative to its 50-day, 200-day, and 52-week technical levels?
QTTB last traded at $8.91 (+0.45% on volume of 268,192 shares), positioning the stock -13.58% below its 50-day simple moving average ($10.31) and -3.78% below its 200-day simple moving average ($9.26). Across its 52-week range of $1.90 to $23.57, QTTB sits at the 32.3% percentile with a 14-day RSI of 47.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.80 to $10.02).
QTTB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is QTTB stock moving today?
Why QTTB Stock advanced +0.45% Today — RQD Quant Desk Flash. Stretched risk/reward at 9x P/E (85% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 53/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
QTTB — Q32 Bio Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:39:39Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating is 53, graded D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim" (per the Roarable RQD rating). The five pillars are:
- Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, this pillar cites ROIC of 85% and FCF yield of -12.7%. The high ROIC contrasts with negative free cash flow, so the return on capital is not yet translating into cash generation for shareholders.
- Whale / 13F Flow: 6 / 20. The pillar is labeled as covering institutional accumulation and options positioning. No holder data is supplied in the sources, so the score cannot be traced to specific positions.
- Insider Conviction: 10 / 20. The pillar covers SEC Form 4 and Congressional PTR cluster flow. The news wire does reference an executive stock sale (see Catalysts), but the sources do not provide the Form 4 detail needed to assess conviction.
- Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0, and the pillar reflects sector sensitivity.
- Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this pillar cites Altman Z 5.99, Piotroski F 4/9, and Debt/Equity 0.5. This is the strongest pillar.
For a prospective investor, the rating points to a weak overall setup despite a stronger balance sheet. Negative FCF yield, weak institutional and insider signals, and a sector-sensitive macro profile weigh on the score, while the forensic balance sheet and high reported ROIC partially offset it. The valuation context in the market data is mixed: a trailing P/E of 8.9 and forward P/E of 8.3 look low on earnings, but the FY 2025 earnings figure is not clearly tied to recurring operations, and EV/EBITDA of 12.8 and negative FCF yield suggest the market is not treating those earnings as durable cash. Upside drivers would need to come from sustained cash conversion, which the sources do not yet show. This is an analytical summary, not personalized financial advice.
Snapshot
Business
Q32 Bio Inc. (QTTB) is listed on NASDAQ and sits in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile describes it as an issuer with a market capitalization of $0.3B. The sources do not describe its products, customers, or revenue model. Revenue details are available only as reported financial figures (see Financial Trend).
Recent Catalysts & News Wire Analysis
- Executive sales (news wire, YELLOW): Reports describe a CEO stock sale of $26,798 and a CSO stock sale of $7,629, plus a scientific chief sale of 917 shares tied to automatic tax withholding. These are small in dollar terms but are insider sales, which is a risk watch item.
- Institutional passive stake (news wire, YELLOW): A report describes a passive Q32 Bio stake disclosed by Bank of America and three subsidiaries.
- Catalyst-tagged item (news wire, GREEN): A Yahoo Finance headline references a 28.5% analyst-expected rally for a different company, ITT (ITT). It is tagged CATALYST in the feed, but it is not specific to QTTB and should not be treated as a QTTB catalyst.
- Symbol reference (news wire, YELLOW): A TradingView item references the ticker BIOA rather than QTTB and carries no QTTB-specific content.
- Butterfly Supply-Chain Graph: Supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What products or pipeline assets generate the FY 2025 revenue of $53.7M, and is that revenue recurring?
- What drove the swing from FY 2024 and FY 2023 operating losses to FY 2025 operating income of $16.9M, and is it repeatable?
- Why is FCF negative ($-33.5M in FY 2025) when net income is $29.8M, and what is the cash conversion path?
- What are the debt amount, EPS, and gross profit figures, given they are listed as N/A or 0% in the sources?
- What are the terms and scope of the Bank of America passive stake, and what is the institutional holder composition?
QTTB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Q32 Bio Inc. (QTTB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 15m ago
Q32 Bio CEO Jodie Morrison sells $26,798 in stock Investing.com report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 3h ago
Q32 Bio (QTTB) scientific chief sells 917 shares automatically to cover tax withholding. Stock Titan report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 6h ago
Does ITT (ITT) Have the Potential to Rally 28.5% as Wall Street Analysts Expect? Yahoo Finance report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 9h ago
BIOA Stock Price and Chart — NASDAQ:BIOA TradingView report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 12h ago
Bank of America reports a passive Q32 Bio (QTTB) stake for itself and three subsidiaries. Stock Titan report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 15h ago
Q32 bio CSO Shelia Violette sells $7,629 of company stock By Investing.com Investing.com UK report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 18h ago
Q32 (QTTB) Slides -1.70% as Selling Pressure Mounts 2026-10-24 - Wave Equality https://www.siam.in/ report covering Q32 Bio Inc. (QTTB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 21d ago
Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40 Leerink Partners analyst Will Soghikian initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $40.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
QTTB Bull vs. Bear Conversation Board — What's Your Call at $8.91?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QTTB 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $9.58 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is QTTB (D+ • RQD 53/100) a Buy at $8.87?
Welcome to the QTTB (Q32 Bio Inc.) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $7.36 (-17.0%)
Spot @ $8.87 Pump the brakes on QTTB — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on QTTB, but look at what you are paying: 8.9x trailing P/E with tightening sector spreads. Unless Q32 Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $10.20 (+15.0%)
Spot @ $8.87 QTTB cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on QTTB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.87 (52-wk range $1.90 - $23.57), any beat on forward guidance forces shorts and underweight funds to chase.